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Abstract
Purpose: The purpose of this study is to investigate the effect of the inhaled gas used alongside
isoflurane in the anesthetization of small animals on the time-intensity curves (TICs) acquired
from ultrasound contrast agents—microbubbles.
Procedures: TICs were recorded over the common iliac vein of 12 mice receiving Definity®.
Animals were anesthetized with isoflurane, the ventilator was driven by medical air (MA), then in
random order, the driving gas was changed for 3 min to: MA (control); pure oxygen (O2); O2+
perfluorohexane (PFH:O2); or O2+octafluoropropane (OFP:O2), the perfluorocarbon (PFC) in
Definity, followed by a return to MA 3 min later.
Results: The mean slope of signal decay was −0.47, −1.05, −1.16, and −1.42 video-intensity
units/s for MA, OFP:O2, PFH:O2, and O2, respectively; MA had the slowest decay (pG0.0001).
Both PFC mixtures had slower signal decay than O2, but only OFP:O2 was significant (pG0.01).
When MA was used immediately following dosing, slope gradually decreased (p=0.032) and
was two times slower by the fourth injection (p=0.012).
Conclusions: Microbubble kinetics are closely associated with the driving gas for inhaled
anesthesia. MA has the least effect and should be used when inhaled anesthesia is used.
Furthermore, when animals are given multiple injections in the same session, microbubbles last
longer with subsequent injections.
Key words: Contrast-enhanced ultrasound, Microbubbles, Definity, Gas anesthesia, Mice,
Oxygen, Medical air, Microbubble quantification, Microbubble half-life
Introduction
C
ontrast-enhanced ultrasound (CEUS) is gaining increas-
ing importance in clinical and research applications.
The microbubble-based ultrasound contrast agents (UCAs)
used to enhance tissues differ dramatically from magnetic
resonance and x-ray computed tomography agents in that
ultrasound is extremely sensitive to microbubbles (MBs) and
is capable of detecting a single moving MB [1], allowing for
sub-trace doses, and, owing to their 1–3-μm size, MBs
remain within the vascular space. In addition to their
promising diagnostic use, MBs can be used to increase local
drug and gene delivery for more effective therapy. These
facts have resulted in rapid expansion of CEUS clinical
applications, and have accelerated pre-clinical research to
develop potential uses in molecular imaging-based diagnos-
tic and therapeutic techniques.
Cancer detection with targeted MBs is a promising pre-
clinicalapplicationthatisbeingtranslatedtotheclinic.Muchof
the pre-clinical effort has focused on rodent models of tumor
angiogenesis, ischemia, thrombosis, and inflammation [2]. For
studies that assess perfusion [3], receptor density [4], and
differential contrast characteristics [5], MB signal quantifica-
tion and kinetics in the region of interest that is typically
monitoredbyacquiringatime-intensitycurve(TIC)arecritical. Correspondence to: Robert F. Mattrey; e-mail: rmattrey@ucsd.eduWhile the TIC is crucial for studying kinetics in a region of
interest, the observed kinetics include, in addition to local
physiologic indices, MB loss from the systemic circulation
caused by MB elimination and MB destruction by ultrasound
itself. MB formulation affects both kinetics and the MBs’
sensitivitytoultrasound,causingdifferent eliminationrates [6–
8]; however, MB elimination is also affected by the inhaled
gases, particularly oxygen (O2), used when performing in vivo
studies [9–11]. Former studies focused on Albunex and
Optison, which have albumin shells, and Albunex is air filled.
Fortunately, the majority of human studies and the animal
studies done with injectable anesthesia are performed with the
subject breathing room air. In few patients’ studies and in the
majorityofrodentstudies,imagingisperformedwith100%O2
inhalation that negatively impacts MB survival [11]. Gas
anesthesia is preferred, particularly in small animals, because
injectable anesthesia impacts homeostasis and provides a
narrow safety margin [12].
Gas anesthesia requires a pressurized gas to drive the
ventilator. Further, CEUS studies are being performed in
rodents with gas anesthesia that use signal enhancement and/
or TICs as end-points without mentioning or controlling the
driving gas used [4, 13–18]. It is therefore prudent to define
the influence of inhaled gases on MB survival within the
vascular space in rodents.
The primary purpose of this study was therefore to
investigate in mice the effect of the pressurized gas used
during gas anesthesia on MB survival. There were two
secondary aims for this study: (1) Since MBs’ perfluorocarbon
(PFC) gas core is exhaled because of the lower partial pressure
gradient between the blood and alveolar space [19, 20], we
hypothesized that adding PFC vapor to the inhaled gas could
slow the PFC loss and increase MB survival. (2) Since many
experiments include multiple injections of either the same MB
formulation or targeted vs. non-targeted MBs, and since PFC
can remain in the circulation and lungs for 1–2h[ 20], we also
aimed to assess whether a MB injection whose ultrasound




We used four different pressurized gases to drive the
ventilator to administer isoflurane anesthesia. Once the
experiment began, the isoflurane and gas flow were
maintained constant. We used medical air (MA); pure O2;
a mixture of O2 and octafluoropropane (OFP), the gas core
used in Definity®, the only commercially available MB in
the USA; and a mixture of O2 and perfluorohexane (PFH).
PFH was used to determine whether any PFC could affect
the survival of an OFP-filled MB.
MA is composed of 5% CO2,2 1 %O 2, and 74% nitrogen
(Airgas West, Lakewood, CA, USA). The O2 was ≥99% pure
(Praxair, Inc., Danbury, CT, USA). The PFCs were ≥98% pure
(SynQuest Labs, Inc., Alachua, FL, USA). They were mixed
with O2 in a sealed plastic bag and then pressurized to flow
through the anesthesia system. Being a gas, OFP was mixed
directly with pure O2. Since PFH is liquid at room temperature
(BP=55°C), pure O2 was percolated through PFH using two
diffusers connected in series to saturate O2 with PFH vapor.
The generated PFC:O2 mixtures were analyzed by gas
chromatography (HP-GC-5890 Series II®, Hewlett-Packard
Company, Houston, TX, USA) with a GS-Q column. The ratio
of OFP in the OFP:O2 mixture ranged from 50% to 70% and
PFH in the PFH:O2 mixture from 51% to 66% by volume.
Animal Model
The experiment used 15 7- to 9-week-old NIH Swiss mice
(Harlan Laboratories). All animals were induced using MA
and isoflurane (1.5–2%) and placed supine on a heated table
integrated into the Visualsonics Vevo770 small-animal
imaging system (VisualSonics, Toronto, Ontario, Canada).
The groin and neck were clipped and the remaining hair
removed with a depilatory cream. The right jugular vein was
surgically exposed for direct MB injection. All procedures
were pre-approved by the Institutional Animal Care and Use
Committee.
UCA and Injection
Definity (lot# 4579, distributed by Lantheus Medical
Imaging) was used for all experiments. Each vial was
prepared as instructed by the manufacturer by shaking for
45 s using the apparatus provided by the manufacturer
(Bristol-Myers Squibb Medical Imaging, Inc., North Bill-
erica, MA, USA). Microbubbles within the vial were re-
suspended by hand agitation for 10 s just before dosing.
Since each mouse was injected four times per session, all
doses were withdrawn from the same vial within 4 h and
the vial discarded. Injections of 1/20 dilution were
prepared by mixing 0.01 mL of Definity with 0.19 mL
of normal saline in a 0.3-mL syringe using a 28-gauge
needle. The suspension in the syringe was prepared
immediately prior to each injection.
Image Acquisition
The imaging protocol is shown in Fig. 1.T h e4 0 - M H z
transducer (RMV706) was used to image the common
iliac veins in the transverse plane using standard B-mode.
A region-of-interest was positioned within the vein and
was not moved throughout the entire observation period.
Video signals were measured by the instrument in real
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When at least 10 s were recorded at baseline while the
animal was still on MA, 0.1 mL of the diluted contrast
was administered slowly over 10–15 s and the signal
recorded for 2 min. At 2 min post-dosing, the pressurized
g a sw a sc h a n g e dt oe i t h e r :( a )M A ,w h i c hs e r v e da s
control; (b) O2;( c )O 2+OFP (OFP:O2); or (d) O2+PFH
(PFH:O2), selected at random using a random number
generator, and the signal recorded for an additional 3 min.
The pressurized gas was then returned to MA for an
additional 3 min of signal recording. The video signal
within the vein for the entire 8-min observation period
was saved as a numerical data file for analysis. Signal
was monitored until it returned to baseline or for 30 min
after contrast administration, whichever was greater. Each
mouse received four injections within the same exper-
imental session, with one injection for each pressurized
gas.
Data Reduction
Three animals died before completing all four injections,
resulting in 12 complete mice (48 injections) whose data was
used for analysis. Video signals in the iliac vein were plotted
over time for each of the three observation periods for each
experimental gas (Fig. 2). Because the frame-to-frame signal
was highly variable due mostly to pulsatile motion from the
adjacent artery, a 50-point moving average (10 s of data)
was calculated and plotted. A linear regression was fitted to
Fig. 1. Imaging protocol of each mouse. Injections were given when mice were breathing medical air (MA). At 2 min after
injection, they were switched to the Exp. Gas that was either MA, O2, OFP:O2, or PFH:O2—given in random order, and the
signal monitored for 3 min. They were then returned to MA and monitored for an additional 3 min. Each mouse received four
injections of 0.1 mL of 1/20 dilution of Definity at least 30 min apart when signal returned to baseline.
Fig. 2. Typical example of venous signal from the same mouse following two separate injections when it was breathing
MA during periods 1 and 3 of both injections and MA (above curve)o rp u r eO 2 (bottom curve) during period 2. The high
frame-to-frame signal variation was smoothed by calculating a 50-point (10 s of data) moving average (thick white line).
The data from the moving average was used to fit a regression line to define the slope of signal decay for each of the
three observation periods. Note that the decay curve in period 2 when the animal was breathing pure O2 (−1.82 units/s) is
four times faster than when breathing MA (−0.43 units/s) in this animal. Also note that when this animal was returned to
MA after O2, signal increased.
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to allow the new gas to fill the alveoli. The slope of signal
decay was calculated for each of the three observation
periods following each injection. Therefore, each mouse
contributed 12 slopes in total: four for MA in period 1 (MA-
baseline); one each for MA, O2, OFP:O2, and PFH:O2 for
period 2; and, finally, four additional slopes for MA in
period 3 (MA-post). Although signal decay is exponential,
the high frame-to-frame variation due to the small region-of-
interest in the iliac veins and motion did not allow accurate
fitting.
Data Analysis
The slopes from all mice for each of the three periods and
for each gas used were averaged and the standard error of
the mean (SEM) calculated. All data analysis was performed
using NCSS2007. A two-way analysis of variance
(ANOVA) was used to evaluate whether the slope of the
signal decay was significantly different between the first,
second, and third observation periods after each injection
and for each of the experimental gases between injections.
The gas and the order it was given (first, second, third, or
fourth) to each mouse were used as the independent
variables. A p value≤0.05 was considered significant. When
a significant effect was detected by ANOVA, a pair-wise
two-tail Student’s t test was then carried out. We used paired
statistics when comparing the slopes among the observation
periods and unpaired statistics when comparing the slopes
between the gases used in period 2. Fisher’s least significant
difference was used as a correction method for the multiple
comparison tests.
Results
When comparing the effect of each gas on the rate of signal
decay in the second observation period, the order in which
the gas was given to each mouse had no effect (p=0.13);
however, there was a marked difference in slopes among the
gases used (pG0.0001). The slopes and their pair-wise
comparisons are shown in Fig. 3. Note that the least decay
was observed when animals were breathing MA (pG0.001),
which was three times slower than when they were breathing
pure O2 (pG0.0001). The addition of slightly more than 50%
by volume PFC to O2 slowed MB decay. While the addition
of PFH to O2 slowed the decay rate by 19%, the difference
was not statistically significant (p=0.126). However, when
the PFC was the same as that filling the MB core, signal
decay slowed by 26% (p=0.006).
Signal decay when MA was used throughout the three
observation periods in the same mouse was identical (−0.41±
0.08 for MA pre, −0.47±0.07 for MA, and −0.49±0.04 for
MA post, p=0.41). Comparing the MA-post signal decay to
the MA-pre decay after mice were breathing either O2, OFP:
O2 or PFH:O2, the decay rate was 2.6 times slower (MA-
baseline; −0.55±0.05 vs. −0.22±0.06; p=0.0003), even
though animals were breathing MA in both periods; this
suggests a partial signal recovery when the animal was
returned to breathing MA. This is illustrated in Fig. 4,w h e r e
theoretical TICs were constructed based on the mean slope
Fig. 3. The average slope and SEM are shown for MA at baseline (MA-pre) (period 1) and MA-post (period 3), and for all four
individual gases used in period 2. Since MA pre- and post- were acquired with every injection, the mean and SEM were
calculated from all 48 injections. The values for the individual gases are based on the 12 injections, one from each mouse. Pair-
wise comparisons are as shown. All other paired comparisons that are not shown were not statistically significant.
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gases used.
Although all animals were breathing MA during the first
observation period, analysis of signal decay during this
period revealed that while the gas to be used in period 2 had
no effect on slope as would be expected (p=0.146), the
injection order had a significant effect (p=0.032). The slope
during the first observation period and the SEM as a
function of injection order are shown in Fig. 5. Note that
the fastest signal decay occurred after the first injection.
Signal decay slowed with subsequent injections and was two
times slower by the fourth injection (p=0.012).
Discussion
The results of this study show that inhaled gases have a
profound effect on MB survival in the systemic circulation
and is in concordance with the results recently reported by
Mullen et al. who modeled the effect of ambient gases on
the rate of change of MB size [21]. The Definity used in this
study—the only ultrasound contrast agent clinically avail-
able in the USA—is a suspension of MBs filled with pure
OFP (C3F8), a PFC with low plasma solubility. These MBs
initially swell when administered intravenously, as the OFP
acts as an osmotic agent driving in oxygen (O2) and nitrogen
(N2) into the MB [8, 22]. As MBs that have equilibrated with
venous blood traverse the pulmonary circulation, gases within
the MBs equilibrate with those filling the alveolar space. Not
only will their N2 and O2 content exchange, but their PFC is
lost to the alveoli and is subsequently exhaled [20]. Further-
more, the ambient blood and insonation pressures and the lipid
composition of the MB shell will affect the multi-gas
equilibriums as the MBs circulate through the circulation and
as they pass through a region being insonated [7, 8, 21–23].
Ultimately, as the PFC vapor within the MB decreases, the
surface tension combined with the ambient pressure, partic-
ularly when ultrasound peak pressure is added, the vapor
pressure of the PFC is exceeded and the PFC becomes liquid
and loses its ultrasound backscatter advantage [22, 24].
Relative to red blood cells, liquid PFC droplets are seven to
eight times morereflective, while MBs are atleast ten ordersof
magnitude more reflective [25, 26].
It was observed that when Albunex, the first agent
approved for human use that used denatured albumin to
encapsulate air, was injected intravenously into animals
breathing nitrous oxide and O2, no signal was detected in the
left ventricle [11]. With the animals still breathing O2,M B s
reached the left ventricle when a PFC was added to the MB
core [10]. In our study, MBs filled with pure PFC
disappeared from blood three times faster when animals
breathed O2 compared to medical air.
The N2 that makes up approximately 80% of the gas in
the alveolar space and the gas dissolved in blood is not
consumed by the organism, serving to stabilize the MB as
was very recently shown by Mullen et al.[ 21], when they
modeled gas transport across MBs. Our results also show
that the loss of PFC to the alveolar space is a factor since the
addition of PFC to pure oxygen in the inhaled gas increased
MB survival. It appears that when OFP was added, MBs
survived slightly longer in the circulation than when PFH
was added (26% vs.. 19%). This suggests that not only is
Fig. 4. Theoretical time-intensity curves constructed by
starting from an arbitrary 400 video-intensity units and
applying the mean slope associated with MA-baseline, each
gas used in period 2, and the slope during MA-post following
each of the four gases. The error bar reflects the error
calculated based on the SEM for each of the three periods for
each gas. Since the slopes during MA-baseline for each gas
were not statistically different, the mean MA-baseline slope
and SEM for all injections were used for clarity. Note that
when MA was used in period 2, the decay curve throughout
all three observation periods is nearly linear. The decay rate
in period three while the animals are breathing MA following
the use of gases other than MA in period 2, slows by 2.6
times (p=0.0003).
Fig. 5. Slope of signal decay±SEM while the animal is
breathing MA immediately following contrast administration
in period 1 prior to switching the gas. The slope is plotted
against the injection order of four consecutive injections. Note
thatthesignalislostataslowerrate,withsubsequentinjections
doubling microbubble survival by the fourth injection.
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type of PFC used could also have an effect. While OFP that
fills the MB core could be superior to PFH when it fills the
alveolar space, it is possible that the PFC that is not
consumed by the organism served the role of N2, and OFP
was more effective than PFH in that function. However, the
difference between OFP and PFH could also be due to the
fact that PFH is liquid at room and body temperatures and
could not achieve the same partial pressure as OFP. Although
we used two stations to fully saturate the O2 gas with PFH
vapor,itmightnothavebeensufficient.Pleasenotethattheuse
of PFCs in this experiment was not intended as an approach to
lengthen MB survival, but rather to gain insight into a possible
mechanism of MB longevityt in vivo. It should also be noted
that adding PFC to inhaled gases is costly, impractical, and
much less effective than MA.
We noted in this study that the decay rates were identical
when animals breathed MA throughout all three observation
periods; however, when animals breathed O2 or either of the
PFCmixturesinthesecondperiod,thedecayrateduringthefirst
period was 2.6 times faster than in the third period. The example
in Fig. 2, in fact, shows a positive slope in period 3 following O2
breathing, indicating not only slowing of MB decay but also
signal recovery in this animal. Among all animals, however,
there continued to be signal decay in the third period, albeit at a
slower rate (see Fig. 4). This observation suggests that some
MBs that were in the process of shrinking due to the absence of
N2 re-inflated fully or partially when N2 was provided [22],
This study also showed that there was a detectable
interference of one injection on MB survival on subsequent
injections. Each mouse received four injections separated by
at least 30 min or when blood signal had returned to
baseline, whichever was longer. All injections were given
when animals were breathing MA prior to switching the
inhaled gas. Microbubble survival increased with subsequent
injections and slightly more than doubled by the fourth
injections. This is likely due in part to an increasing PFC
level in the mouse from one injection to the next. When
blood and exhaled gases were monitored in human subjects,
perfluorobutane (C4F10) was still detectable at 2 h after
injection [20]. Although OFP (C3F8) is more volatile than
perfluorobutane and would likely be lost in a shorter period,
it is expected that some OFP would still be present by
30 min to slow PFC loss. Further, PFC gas is heavier than
air and will likely not wash-out rapidly from the lung, slowly
decreasing the rate of PFC loss to the alveoli. Finally, as
MBs collapse into liquid and become invisible on ultrasound
[8, 22], their PFC is available to transfer to MBs because of
the large partial pressure gradient between the liquid and
gaseous phases, increasing MB survival.
Conclusions
Gas anesthesia with isoflurane is the preferred and the most
commonly used method to anesthetize mice for imaging. With
increasing number of studies using microbubble-based ultra-
sound contrast in molecular imaging, it is critical to control for
the effect of the pressurized gas used since it could have
profoundeffectsonMBsurvivalandsignal.Thisisparticularly
important in those studies that use tissue signal or time-
intensity curves as end-points for efficacy. These studies
should at least report the inhaled gas used. The fact that MA
was the gas with the longest MB survival is advantageous,
since MA is inexpensive, safe, and widely available. Since
multiple injections are typically used in the same mouse to
compareoneformulationofMBstoanotheroroneintervention
to another, it is prudent to space the injections as far apart as is
feasible to minimize the interference of one injection upon the
other.Knowingthis,itisalsopossibletodesigntheexperiment
to control for this potential bias.
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